Literature DB >> 11901210

Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition.

Hiroshi Uchino1, Yoshikatsu Kanai, Do Kyung Kim, Michael F Wempe, Arthit Chairoungdua, Emiko Morimoto, M W Anders, Hitoshi Endou.   

Abstract

The L-type amino acid transporter 1 (LAT1) is an Na(+)-independent neutral amino acid transporter subserving the amino acid transport system L. Because of its broad substrate selectivity, system L has been proposed to be responsible for the permeation of amino acid-related drugs through the plasma membrane. To understand the mechanisms of substrate recognition, we have examined the LAT1-mediated transport using a Xenopus laevis oocyte expression system. LAT1-mediated [(14)C]phenylalanine uptake was strongly inhibited in a competitive manner by aromatic-amino acid derivatives including L-dopa, alpha-methyldopa, melphalan, triiodothyronine, and thyroxine, whereas phenylalanine methyl ester, N-methyl phenylalanine, dopamine, tyramine, carbidopa, and droxidopa did not inhibit [(14)C]phenylalanine uptake. Gabapentin, a gamma-amino acid, also exerted a competitive inhibition on LAT1-mediated [(14)C]phenylalanine uptake. Although most of the compounds that inhibited LAT1-mediated uptake were able to induce the efflux of [(14)C]phenylalanine preloaded to the oocytes expressing LAT1 through the obligatory exchange mechanism, melphalan, triiodothyronine, and thyroxine did not induce the significant efflux. Based on the experimental and semiempirical computational analyses, it is proposed that, for an aromatic amino acid to be a LAT1 substrate, it must have a free carboxyl and an amino group. The carbonyl oxygen closer to the amino group needs a computed charge of -0.55 approximately -0.56 and must not participate in hydrogen bonding. In addition, the hydrophobic interaction between the substrate side chain and the substrate binding site of LAT1 seems to be crucial for the substrate binding. A substrate, however, becomes a blocker once Connolly accessible areas become large and/or the molecule has a high calculated logP value, such as those for melphalan, triiodothyronine, and thyroxine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11901210     DOI: 10.1124/mol.61.4.729

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  97 in total

1.  Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.

Authors:  Sagar Agarwal; Yasuo Uchida; Rajendar K Mittapalli; Ramola Sane; Tetsuya Terasaki; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2012-03-08       Impact factor: 3.922

2.  Human CNS barrier-forming organoids with cerebrospinal fluid production.

Authors:  Laura Pellegrini; Claudia Bonfio; Jessica Chadwick; Farida Begum; Mark Skehel; Madeline A Lancaster
Journal:  Science       Date:  2020-06-11       Impact factor: 47.728

3.  Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.

Authors:  Michael B Bolger; Viera Lukacova; Walter S Woltosz
Journal:  AAPS J       Date:  2009-05-12       Impact factor: 4.009

Review 4.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Substrate binding tunes conformational flexibility and kinetic stability of an amino acid antiporter.

Authors:  Christian A Bippes; Antra Zeltina; Fabio Casagrande; Merce Ratera; Manuel Palacin; Daniel J Muller; Dimitrios Fotiadis
Journal:  J Biol Chem       Date:  2009-05-06       Impact factor: 5.157

Review 6.  CATs and HATs: the SLC7 family of amino acid transporters.

Authors:  François Verrey; Ellen I Closs; Carsten A Wagner; Manuel Palacin; Hitoshi Endou; Yoshikatsu Kanai
Journal:  Pflugers Arch       Date:  2003-06-11       Impact factor: 3.657

Review 7.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.

Authors:  C Rosilio; M Nebout; V Imbert; E Griessinger; Z Neffati; J Benadiba; T Hagenbeek; H Spits; J Reverso; D Ambrosetti; J-F Michiels; B Bailly-Maitre; H Endou; M F Wempe; J-F Peyron
Journal:  Leukemia       Date:  2014-12-08       Impact factor: 11.528

9.  Mouse system-N amino acid transporter, mNAT3, expressed in hepatocytes and regulated by insulin-activated and phosphoinositide 3-kinase-dependent signalling.

Authors:  Sumin Gu; Paul Langlais; Feng Liu; Jean X Jiang
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

10.  LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.

Authors:  Arik A Zur; Huan-Chieh Chien; Evan Augustyn; Andrew Flint; Nathan Heeren; Karissa Finke; Christopher Hernandez; Logan Hansen; Sydney Miller; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2016-09-03       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.